Evidence map›Paper›PMID 29695765›Full record

ArticleBritish journal of cancer2018

Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers.

Shiraj Sen, Shumei Kato, Rishi Agarwal, Sarina Piha-Paul, Kenneth Hess, Daniel Karp, Filip Janku, Siqing Fu, Aung Naing, Shubham Pant and 15 more

Open access · hybridAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Clinical immunotherapy in pancreatic cancer.Cancer immunology, immunotherapy : CII · 2024
    Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 3 institutions in 1 country.

Shiraj SenDivision of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Shumei KatoDepartment of Medical Oncology, University of California at San Diego, San Diego, CA, 92103, USA.
Rishi AgarwalDepartment of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Sarina Piha-PaulDepartment of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Kenneth HessDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Daniel KarpDepartment of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Filip JankuDepartment of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Siqing FuDepartment of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Aung NaingDepartment of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Shubham PantDepartment of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Gerald FalchookSarah Cannon Research Institute at HealthONE, Denver, CO, 80218, USA.
Chad TangDepartment of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Xifeng WuDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Yuanqing YeDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Apostolia TsimberidouDepartment of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Vivek SubbiahDepartment of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Razelle KurzrockDepartment of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Lauren ByersDepartment of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Shannon WestinDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
JoAnn LimDepartment of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Stacie BeanDepartment of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Allison BassDepartment of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Ly NguyenDepartment of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Funda Meric-BernstamDepartment of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
David HongDepartment of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. dshong@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USHealthONE · USUniversity of California San Diego Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe performed a phase I modified 3 + 3 dose escalation study to evaluate the safety and activity of bevacizumab plus gemcitabine and nab-paclitaxel in patients with advanced solid tumours.

methodsPatients were given fixed dose gemcitabine plus increasing doses of nab-paclitaxel and bevacizumab. Toxicity, response, and association with VEGF polymorphism was analysed.

resultsThe study enrolled 110 patients who had undergone a median of 3 prior lines of therapy. The median age was 60 years (range, 17-85 years), and 55 patients (50%) had gemcitabine-refractory disease. We observed 3 dose-limiting toxicities during dose escalation and 3 DLTs in expansion cohorts. Dose escalation to 150 mg/m

conclusionsThe combination of gemcitabine, nab-paclitaxel, and bevacizumab is safe, well-tolerated, and has activity in advanced malignancies, including gemcitabine-refractory tumours. Based on this study, the recommended phase 2 dose is gemcitabine 1000 mg/m

Indexed as

AdolescentAdultAgedAged, 80 and overAlbuminsAntineoplastic Combined Chemotherapy ProtocolsBevacizumabDeoxycytidineDrug Administration ScheduleFemaleGemcitabineHumansMaleMaximum Tolerated DoseMiddle AgedNeoplasms130-nm albumin-bound paclitaxelAlbuminsBevacizumabDeoxycytidineGemcitabinePaclitaxelVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID29695765
PMCPMC5988803
OpenAlexW2800251312

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.